Skip to main content
Clinical Trials/NCT07742839
NCT07742839Not yet recruitingNot Applicable

Clip for LAA closuRe: Evaluating the Safety and Effectiveness of the ECLIPTIS Exclusion sYstem (CLAARITY Study)

Edwards Lifesciences0 sites168 target enrollmentStarted: September 30, 2026Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
168
Primary Endpoint
Percentage of participants who have device technical success

Study Overview

Brief Summary

CLAARITY is a prospective, observational, single-arm, multi-center, post-market US study designed to evaluate the safety and performance of the ECLIPTIS clip in a minimum of 168 participants.

Detailed Description

Subjects in the CLAARITY study will be enrolled at up to 15 sites in the United States. The population will be subjects who will be implanted with the ECLIPTIS clip who are eligible for LAA exclusion when undergoing concomitant open-heart cardiac surgical procedure according to its labeled Instructions for Use (IFU).

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ≥18 years old
  • Willing and able to provide consent and comply with study follow-up requirements
  • Scheduled to undergo concomitant open-heart cardiac surgery with planned implantation of ECLIPTIS clip for LAA exclusion per IFU

Exclusion Criteria

  • Known life expectancy <1 year
  • Previous cardiac surgery (re-operation)
  • Prior LAA isolation attempts
  • Planned right thoracotomy approach
  • Concomitant open-heart surgery that is considered an emergency
  • Thrombus in left atrium/LAA that cannot be evacuated before placement of clip
  • Based on intraoperative evaluation, LAA is not appropriate for exclusion prior to positioning ECLIPTIS clip to the base of the LAA

Outcomes

Primary Outcomes

Percentage of participants who have device technical success

Time Frame: Intra-operative

Successful ECLIPTIS clip placement and exclusion of LAA, defined as absence of flow (0 mm) between left atrium and LAA, and \<10 mm of residual stump proximal to the clip at the time of the procedure assessed by intra-operative transesophageal echocardiogram (TEE) with Doppler.

Participant's rate of major clinically significant adverse events

Time Frame: 30 days

Major clinically significant adverse events related to the ECLIPTIS clip and/or ECLIPTIS clip placement procedure within 30 days: * Death * Major bleeding * Major infection * Pericardial effusion requiring intervention * Myocardial infarction requiring intervention * Stroke, systemic embolism

Secondary Outcomes

  • Percentage of participants who have device technical success(90 days)
  • Participant's rate of major clinically significant adverse events over time(90 days, 1, 2, and 3 years)

Investigators

Sponsor
Edwards Lifesciences
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials